Agallamh na Miosa: Gabriel Rosenstock ag caint le: Willem M. Roggeman

Rosenstock, Gabriel; Roggeman, Willem M.

doi:10.2307/25571396

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…10 The efficacy and safety of lixisenatide have been investigated extensively across the GetGoal clinical trial programme, which included patients with T2D with or without renal impairment. [13][14][15][16][17][18][19][20][21][22][23] Overall, these studies have demonstrated that lixisenatide is significantly more effective than placebo at reducing levels of glycated haemoglobin (HbA1c). Moreover, treatment with lixisenatide was associated with significant reductions in postprandial plasma glucose (PPG) and fasting plasma glucose (FPG) compared with placebo.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment

Hanefeld¹,

Arteaga

Leiter

et al. 2017

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

AimsThis post hoc assessment evaluated the efficacy and safety of once‐daily, prandial glucagon‐like peptide‐1 receptor agonist lixisenatide in patients with type 2 diabetes (T2D) and normal renal function (estimated glomerular filtration rate ≥90 mL/min), or mild (60‐89 mL/min) or moderate (30‐59 mL/min) renal impairment.MethodsPatients from 9 lixisenatide trials in the GetGoal clinical trial programme were categorized by baseline creatinine clearance: normal renal function (lixisenatide n = 2094, placebo n = 1150); renal impairment (mild: lixisenatide n = 637, placebo n = 414; moderate: lixisenatide n = 122, placebo n = 68). Meta‐analyses of placebo‐adjusted mean differences between baseline renal categories were performed for efficacy and safety outcomes.Results HbA1c, 2‐hour postprandial plasma glucose and fasting plasma glucose were comparably reduced in lixisenatide‐treated patients with normal renal function, and mild and moderate renal impairment. The most common adverse events (AEs) in all renal function categories were gastrointestinal (GI), predominantly nausea and vomiting. A 14% higher incidence of GI AEs and a 10% higher incidence of nausea and vomiting were seen with mild impairment vs normal function (P = .003 for both), but no significant differences were observed between the mild and moderate impairment categories (P = .99 and P = .57, respectively), or between the moderate impairment and normal categories (P = .16 and P = .65, respectively). Additionally, the incidence of hypoglycaemia was similar in all categories.ConclusionsThis study demonstrates that baseline renal status does not affect efficacy outcomes in lixisenatide‐ vs placebo‐treated patients, and that no lixisenatide dose adjustment is required for patients with T2D with mild or moderate renal impairment.

show abstract